Meeting
2020 ASCO Virtual Scientific Program
Interim data: Phase I/IIa study of EGFR-targeted EDV nanocells carrying cytotoxic drug PNU-159682 (E-EDV-D682) with immunomodulatory adjuvant EDVs carrying α-galactosyl ceramide (EDV-GC) in patients with recurrent, metastatic pancreatic cancer.
Authors
Joanne Lundy
Peninsula and Southeast Oncology, Frankston, VIC, Australia
Joanne Lundy , Gavin M. Marx , Jennifer MacDiarmid , Himanshu Brahmbhatt , Vinod Ganju
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer
Clinical Trial Registration Number
ACTRN12619000385145
Citation
J Clin Oncol 38: 2020 (suppl; abstr 4632)
DOI
10.1200/JCO.2020.38.15_suppl.4632
Abstract #
4632
Poster Bd #
240
Abstract Disclosures
Similar Posters
Poster
2016 Gastrointestinal Cancers Symposium
Evaluation of triptolide pro-drug (Minnelide) as an anti-stromal and anti-tumoral therapeutic option for pancreatic cancer.
First Author: Sulagna Banerjee
Poster
2024 ASCO Annual Meeting
Mind the gap: Estimating the opportunity lost due to the gap between FDA and EMA cancer drug approvals.
First Author: Samantha Gage
Poster
2024 ASCO Annual Meeting
A phase 1/2 study of ubamatamab (REGN4018), a MUC16×CD3 bispecific antibody, administered alone or in combination with cemiplimab (anti–PD-1) in patients with recurrent ovarian cancer or MUC16+ endometrial cancer.
First Author: Els Van Nieuwenhuysen
Poster
2024 ASCO Annual Meeting
Serial circulating tumor DNA monitoring for predicting treatment response and prognosis in patients with pancreatic cancer.
First Author: Jongchan Lee